Hypofractionated stereotactic photon radiotherapy of posteriorly located choroidal melanoma with five fractions at ten Gy--clinical results after six years of experience.

PURPOSE To evaluate long-term safety and efficacy of hypofractionated stereotactic photon radiotherapy with 5 five fractions at 10 Gy each in patients with centrally located choroidal melanoma. MATERIALS AND METHODS Ninety-one patients with centrally located choroidal melanoma were treated stereotactically at a linear accelerator with 6 MV photon beams with 5 fractions at 10 Gy each. Examinations were performed at baseline and every 3 months in the first 2 years, then every 6 months until 5 years and yearly thereafter. Median follow-up was 37.8 months (IQR 19.2-49.9). They included visual acuity assessment, routine ophthalmological examinations with fundoscopy, echography for measurement of tumor dimensions, medical examinations and, if necessary, fluorescein angiography. RESULTS Initial tumor base diameters, height and volume were 11.20mm (IQR 9.10-13.70), 9.80 mm (IQR 7.80-11.70), 4.53 mm (IQR 3.33-6.43) and 253.8mm(3) (IQR 127.5-477.0). Local tumor control and eye retention rates were 97.7% and 86.4% after 5 years, respectively. Eight patients developed metastatic disease and 3 of them died due to metastatic disease during the follow-up period. Median visual acuity decreased from 0.67 initially to 0.05 at the last individual follow-up (p<0.001). The most common toxicities (any grade) were radiation retinopathy (n=39), optic neuropathy (n=32), radiogenic cataract (n=21), neovascular glaucoma (n=15) and dry eye syndrome (n=10). The 5 year probabilities to remain free of these side effects (any grade) were 26.0%, 45.4%, 55.4%, 72.6% and 80.5%, respectively. The most important prognostic factors for toxicities were the largest tumor base diameter, tumor height and tumor distance to the optic disk. CONCLUSION Hypofractionated stereotactic photon radiotherapy with a total dose of 50 Gy delivered in 5 fractions is a highly effective treatment option in patients with centrally located choroidal melanoma and has a moderate toxicity profile.

[1]  Bo Henry Lindqvist,et al.  Competing risks , 2014, Lifetime data analysis.

[2]  Roman Li.  Leksell gamma knife treatment of uveal melanoma , 2002 .

[3]  Stefan Sacu,et al.  Radiogenic side effects after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. , 2012, International journal of radiation oncology, biology, physics.

[4]  E. Gragoudas.  Proton beam irradiation of uveal melanomas: the first 30 years. The Weisenfeld Lecture. , 2006, Investigative ophthalmology & visual science.

[5]  B. Damato,et al.  Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. , 2005, International journal of radiation oncology, biology, physics.

[6]  J. Harbour,et al.  Integrative Genomic Analysis of Aneuploidy in Uveal Melanoma , 2008, Clinical Cancer Research.

[7]  Stefan Sacu,et al.  Local tumor control, visual acuity, and survival after hypofractionated stereotactic photon radiotherapy of choroidal melanoma in 212 patients treated between 1997 and 2007. , 2011, International journal of radiation oncology, biology, physics.

[8]  G. Lundell,et al.  Ruthenium brachytherapy for uveal melanoma, 1979-2003: survival and functional outcomes in the Swedish population. , 2005, Ophthalmology.

[9]  Melania Pintilie,et al.  Analysing and interpreting competing risk data , 2007, Statistics in medicine.

[10]  T L Phillips,et al.  15 years experience with helium ion radiotherapy for uveal melanoma. , 1997, International journal of radiation oncology, biology, physics.

[11]  C. Muirhead,et al.  Radiation Cataractogenesis: A Review of Recent Studies , 2009, Radiation research.

[12]  T. Wiegel,et al.  Proton Therapy of Uveal Melanomas in Berlin , 2004, Strahlentherapie und Onkologie.

[13]  Neovascular glaucoma after stereotactic radiotherapy for juxtapapillary choroidal melanoma: histopathologic and dosimetric findings. , 2011, International journal of radiation oncology, biology, physics.

[14]  François DeBlois,et al.  Stereotactic fractionated radiotherapy in the treatment of juxtapapillary choroidal melanoma: the McGill University experience. , 2011, International journal of radiation oncology, biology, physics.

[15]  P. Rama,et al.  Gamma knife radiosurgery for uveal melanoma: 12 years of experience , 2008, British Journal of Ophthalmology.

[16]  C. Shields,et al.  Plaque radiotherapy for uveal melanoma: long-term visual outcome in 1106 consecutive patients. , 2000, Archives of ophthalmology.

[17]  P. Levendag,et al.  Fractionated stereotactic radiotherapy for uveal melanoma, late clinical results. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[18]  L. Desjardins,et al.  Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). , 2006, International journal of radiation oncology, biology, physics.

[19]  T. Wiegel,et al.  Proton therapy of uveal melanomas in Berlin. 5 years of experience at the Hahn-Meitner Institute. , 2004, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al].

[20]  B. Damato,et al.  Cytogenetics of uveal melanoma: a 7-year clinical experience. , 2007, Ophthalmology.

[21]  Ann Schalenbourg,et al.  Eye retention after proton beam radiotherapy for uveal melanoma. , 2003, International journal of radiation oncology, biology, physics.

[22]  E. van Limbergen,et al.  18 Years’ experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma , 2005, British Journal of Ophthalmology.

[23]  E. Gragoudas,et al.  Lens changes after proton beam irradiation for uveal melanoma. , 1995, American journal of ophthalmology.

[24]  A. de Klein,et al.  Clinical and cytogenetic analyses in uveal melanoma. , 2006, Investigative ophthalmology & visual science.

[25]  R Pötter,et al.  A linac-based stereotactic irradiation technique of uveal melanoma. , 2001, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[26]  R. Pötter,et al.  LINAC based stereotactic radiotherapy of uveal melanoma: 4 years clinical experience. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.